

ascorbic acid derivatives, organic compounds having at least one thiol and a alkyl polyhydroxylated and cycloalkyl polyhydroxylated compounds.--

6 --33. The formulation of claim ⁵32 wherein the ascorbic acid derivatives are selected from the group consisting of D-ascorbic acid, L-ascorbic acid, alkali metal ascorbates, alkaline earth metal ascorbates and water-soluble ascorbic acid esters.--

7 --34. The formulation of claim ⁵32 wherein the organic compound having at least one thiol is aliphatic or cycloaliphatic.--

8 --35. The formulation of claim ¹28 containing a free radical scavenger containing at least one thiol is selected from the group consisting of thioglycolic acid, thiolacetic acid, dithiothreitol, reduced glutathion, thiourea, α -thioglycerol, cysteine, acetylcysteine and mercaptoethane sulfonic acid.--

9 --36. The formulation of claim ¹28 wherein the free radical scavenger is an aliphatic polyhydroxy alkanol of 2 to 10 carbon atoms.--

10 --37. The formulation of claim ⁹36 wherein the polyhydroxy alkanol is a cyclic glucitol or a straight chain glucitol of 6 to 10 carbon atoms.--

11 --38. The formulation of claim ⁹36 wherein the polyhydroxy alkanol is glycerol or propyleneglycol.--

12 --39. The formulation of claim ¹⁰37 wherein the cyclic glucitol is selected from the group consisting of mannitol, sorbitol, inositol, glucose and levulose.--

RECEIVED
JUL 18 1999
FBI 1600 GAIL ROOM

13--40. The formulation of claim 28 also containing at least one complexing agent.--

14--41. The formulation of claim 28 wherein the acetaminophen has a concentration of 2 to 350 mg/ml.--

15--42. The formulation of claim 41 wherein the concentration is 60 to 350 mg/ml.--

16--43. The formulation of claim 42 diluted to a concentration of 2 to 50 mg/ml.--

17--44. The formulation of claim 28 also containing an isotonizing agent in an amount to obtain isotonicity.--

18--45. The formulation of claim 28 sterilized by heat treatment.--

19--46. The formulation of claim 28 further containing an effective amount of an analgetic agent.--

20--47. The formulation of claim 46 the analgetic agent is a morphine analgetic selected from the group consisting of natural morphines, semi-synthetic morphines, synthetic morphines, phenylpiperidines, nipecotic acid compounds, phenylcyclohexanol compounds and phenylazepine compounds.--

21--48. The formulation of claim 47 having a concentration of acetaminophen is 0.05 to 5% by weight when morphine is present.--

22--49. The formulation of claim 47 having an acetaminophen concentration of 0.2 to 2.5% by weight when codeine is present.--

23--50. The formulation of claim 28 further containing an anti-inflammatory agent of the phenylacetic acid type.--

24--51. The formulation of claim 50 wherein the anti-

inflammatory agent is ketoprofen.--

25--52. The formulation of claim *28* further containing an antiemetic agent.--

26--53. The formulation of claim *28* further containing an antipileptic agent.--

27--54. The formulation of claim *28* further containing a corticosteroid.--

28--55. The formulation of claim *28* further containing a tricyclic antidepressant.--

REMARKS

Reconsideration of this application is requested in view of the amendments to the claims and the remarks presented herein.

The claims in the application are claims 28 to 55, all other claims having been cancelled. Applicants are submitting herewith a check for \$9.00 for one more claim in excess of 20.

Claims 1, 2 and 4 were rejected under 35 USC 102(b) as being anticipated by the admitted disclosure in lines 18 to 20 of page 1 or in the Abstract of XP739 which, according to the Examiner, teaches paracetamol in aqueous compositions of water and alcohol. Claims 1 to 27 were rejected under 35 USC 103 as being obvious over the teachings of the admitted disclosure in lines 18 to 21 of page 1, XP739, XP737, XP740, XP816, XP817, Fuisz, Ratneraj et al, WO 595